A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates

Abstract

Eradication of tuberculosis (TB), the world's leading cause of death due to infectious disease, requires a highly efficacious TB vaccine. Many TB vaccine candidates are in preclinical and clinical development but only a few can be advanced to large-scale efficacy trials due to limited global resources. We aimed to perform a statistically rigorous comparison of the antigen-specific T cell responses induced by six novel TB vaccine candidates and the only licensed TB vaccine, Bacillus Calmette-Guérin (BCG). We propose that the antigen-specific immune response induced by such vaccines provides an objective, data-driven basis for prioritisation of vaccine candidates for efficacy testing. We analyzed frequencies of antigen-specific CD4 and CD8 T cells expressing IFNγ, IL-2, TNF and/or IL-17 from adolescents or adults, with or without Mycobacterium tuberculosis (M.tb) infection, who received MVA85A, AERAS-402, H1:IC31, H56:IC31, M72/AS01E, ID93+GLA-SE or BCG. Two key response characteristics were analyzed, namely response magnitude and cytokine co-expression profile of the memory T cell response that persisted above the pre-vaccination response to the final study visit in each trial. All vaccines preferentially induced antigen-specific CD4 T cell responses expressing Th1 cytokines; levels of IL-17-expressing cells were low or not detected. In M.tb-uninfected and -infected individuals, M72/AS01E induced higher memory Th1 cytokine-expressing CD4 T cell responses than other novel vaccine candidates. Cytokine co-expression profiles of memory CD4 T cells induced by different novel vaccine candidates were alike. Our study suggests that the T cell response feature which most differentiated between the TB vaccine candidates was response magnitude, whilst functional profiles suggested a lack of response diversity. Since M72/AS01E induced the highest memory CD4 T cell response it demonstrated the best vaccine take. In the absence of immunological correlates of 3 protection the likelihood of finding a protective vaccine by empirical testing of candidates may be increased by the addition of candidates that induce distinct immune characteristics. Author summary Tuberculosis (TB) causes more deaths than any other single infectious disease, and a new, improved vaccine is needed to control the epidemic. Many new TB vaccine candidates are in clinical development, but only one or two can be advanced to expensive efficacy trials. In this study, we compared magnitude and functional attributes of memory T cell responses induced in recently conducted clinical trials by six TB vaccine candidates, as well as BCG. The results suggest that these vaccines induced CD4 and CD8 T cell responses with similar functional attributes, but that one vaccine, M72/AS01E, induced the largest responses. This finding may indicate a lack of diversity in T cell responses induced by different TB vaccine candidates. A repertoire of vaccine candidates that induces more diverse immune response characteristics may increase the chances of finding a protective vaccine a...

A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

“…However, despite the promising results of the M72/AS01E vaccine with 49.7% VE in QFT+ individuals (14), more efficacious vaccines are likely needed to end the epidemic (15). As the first generation of TB vaccine candidates has moved into more advanced clinical trials, there is a recognized need to diversify the vaccine pipeline to maximize the chance of bringing improved TB vaccines into widespread use (18,45,46). Such diversity can come in the form of antigenic composition, delivery vector and immune response functionalities.…”

In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology

“…Different methods have been implemented to develop more effective novel TB vaccines, and among these methods, subunit vaccines have shown great promise 19 i.e., the variety of epitopes in the Mtb protein antigens constituting the subunit vaccine. Besides computational studies, some studies had endeavored to evaluate the human T cell immune responses to multiple Mtb subunit vaccines empirically 20,21 and using data from clinical trials, respectively [22][23][24] . Rodo et al recommended that the identification of vaccines with distinctive immune response features may increase the probabilities of finding a safe vaccine 21 and provided valuable information on the potential production of the Mtb vaccine.…”

Towards new TB vaccines

“…The greatest potential for immune insight would be if the leading candidate TB vaccines induced a diverse immune response. However, in a recent comparison of antigen-specific T cell responses from human clinical trials, the functional profiles suggested a lack of response diversity, with the main difference in the magnitude of response [211]. This comparison involved AERAS-402, H1:IC31, M72/ASO1E, ID93+ GLA-SE, H56:IC31 and MVA85A [211].…”